Viewing Study NCT02122003


Ignite Creation Date: 2025-12-24 @ 7:11 PM
Ignite Modification Date: 2025-12-28 @ 8:43 PM
Study NCT ID: NCT02122003
Status: TERMINATED
Last Update Posted: 2017-11-22
First Post: 2014-04-06
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Second Line Sorafenib After Pazopanib in Patients With RCC
Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module